ArticleJournal of managed care & specialty pharmacy2023
Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States.
Article in Journal of managed care & specialty pharmacy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.
- Efficacy and Safety of Tubeless Hybrid Closed-Loop Systems in Type 1 Diabetes: A Meta-Analysis of Randomized Controlled Trials.Diabetes, obesity & metabolism · 2026Pooled it
- International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Glycemic Targets.Hormone research in paediatrics · 2024Guideline
- Omnipod 5 Delivers Superior Economic Value Compared to Multiple Daily Injections: A Cost-Effectiveness Analysis in Adults With T1D From a Payer Perspective in Sweden.Diabetes, obesity & metabolism · 2026Article
- Plasticizing Diabetes Care: The Metabolic Threat of Plastic-Associated Endocrine Disruptors and Micro-/Nanoplastics in Clinical Medicine.Current diabetes reports · 2026Review
- Cost-Effectiveness of Control-IQ+ Technology in Insulin-Treated Patients With Type 2 Diabetes in the United States.Diabetes, obesity & metabolism · 2026Article
- Assessment of greenhouse gas emission of type 2 diabetes management in adults: a modelling study in the UK.BMJ open · 2026Article
- Role of automated insulin delivery in managing insulin-treated outpatients with type 2 diabetes: A systematic review and meta-analysis.World journal of diabetes · 2025Article
- Diabetes Technology in Saudi Arabia: Current Status and Future Directions.Journal of diabetes science and technology · 2025Review
- Cost-effectiveness analysis model for sotagliflozin compared with insulin monotherapy for patients with type 1 diabetes and chronic kidney disease.Journal of managed care & specialty pharmacy · 2025Article
- Efficacy and Safety of Automated Insulin Delivery Systems in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis (Diabetes Metab J 2025;49:235-51).Diabetes & metabolism journal · 2025Article
- The role of advanced technologies in improving diabetes outcomes.The American journal of managed care · 2025Review
- Use of diabetes technology in children.Diabetologia · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.